Supervillin (SVIL) is a 205kDa protein expressed in the peripheral membrane. It possesses an amino-terminal domain and a carboxyl-terminal domain containing a villin-type domain. The gene encoding SVIL is localized on human chromosome 10p11.2.
Synonyms: Anti-Archvillin; Anti-Supervillin; Anti-p205/p250
MDL Number: MFCD07784599
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: Supervillin (SVIL) binds to F-actin, myosin II and other signaling proteins in lipid rafts. It accelerates the signaling pathways from the epidermal growth factor receptor (EGFR) to extracellular signal-regulated kinases (ERKs). Thus, it coordinates with many proteins to help in cell motility. SVIL increases the contractile nature of myosin II by scaffolding it to long-myosin light chain kinase (L-MLCK). It also contributes to enhance extracellular matrix degradation and reducing the extent of cell-substrate adhesion. SVIL expression in cells have negative effects on thrombus development.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC